J. Craig Venter Institute, Inc.
San Diego, CA
- UEI
- FL8UNYTG72D1
- CAGE
- 3YFD9
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
- San Diego, CA F2RWE2W9BUH4
-
- SAM.gov registration date
- Physical address
- 950 Waterfront Pl #500, San Diego, CA 92101, USA
- Website
- jcvi.org
- Founded
- 1992
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Life Sciences Tools & Services
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $692,088 |
| FY2024 | $712,206 |
| FY2023 | $976,408 |
Contract vehicles
No active vehicles.
1 expired vehicle
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Digital Infuzion, LLC | 75N93021C00007 | $607,491 | |
| Digital Infuzion, LLC | 75N93021C00007 | $2,695,574 | |
| La Jolla Institute For Immunology | 75N93024C00056 | $122,955 | |
| Digital Infuzion, LLC | 75N93021C00007 | $2,105,777 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of Southern California | R01ES031074 | $110,953 | |
| The Trustees Of The University Of Pennsylvania | R01HG012445 | $469,705 | |
| Emory University | U01AI187057 | $359,192 | |
| The Washington University | DESC0022003 | $92,747 | |
| The Trustees Of The University Of Pennsylvania | R01HG012445 | $219,196 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
J. Craig Venter Institute, Inc., a tax-exempt non-profit research organization headquartered in La Jolla, California, serves the federal government as a prime recipient of research grants and a prime contractor on basic-science and biotechnology work, with ancillary subcontractor participation. JCVI operates without SBA set-aside designations and competes on a full-and-open basis across health, life sciences, and defense research portfolios.
JCVI's federal work centers on synthetic biology, genomics, microbiology, infectious-disease research, and biomedical informatics. The organization delivers concrete outputs including engineered bacterial strains and genetic systems, phage therapeutics, genomic sequencing and bioinformatics, machine-learning frameworks for immunoinformatics and cell-type harmonization, and live conferencing and community-building for the synthetic biology field. Representative work includes a $3.6 million firm fixed-price purchase order with the Centers for Disease Control and Prevention (awarded September 2023, completion September 2028) for rapid synthesis of plasmids and mutagenesis in La Jolla; a $320,866 NSF Division of Ocean Sciences grant (CFDA 47.050, awarded August 2026) to investigate microbial composition and metabolite production on sinking particles in the California Current System, with performance through July 2029; and a $529,490 grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855, awarded June 2026, completion May 2028) to engineer a Burkholderia cepacia complex bacteriophage for therapeutic use in cystic fibrosis patients, with work performed in Rockville, Maryland.
JCVI's customer base spans 53 federal agencies, with heavy concentration in the health and life-sciences portfolio. The National Institute of Allergy and Infectious Diseases accounts for 48 awards (nearly 20% of the recent portfolio), followed by the National Science Foundation (30 awards), the broader National Institutes of Health (17 awards), the Department of Agriculture's Agricultural Research Service (16 awards), and NASA Shared Services Center (15 awards). By potential value, the portfolio remains dominated by research grant work; DARPA ranks as the highest-dollar customer at $5.2 million combined potential value across six awards, followed by NASA at $3.8 million across 15 awards. The portfolio concentration is dispersed—the top five customers account for 52% of awards but only 2% of combined potential value, reflecting JCVI's reliance on numerous modest research grants rather than large single contracts.
Activity has fluctuated in recent years, peaking at 24 awards in FY2024 and declining to 9 in FY2026. Ten awards (combined potential value $3.6 million) face ultimate completion within the next twenty-four months, representing modest recompete exposure. SCI-reportable service-contract activity is minimal—only $212 thousand in invoiced prime revenue across FY2024, with 1.6 FTEs delivered on prime SCI contracts that year, and ancillary subcontractor engagement on influenza research data systems. The SCI data signals that JCVI operates primarily as a research grant recipient rather than a federal services contractor; SCI captures only a small slice of the organization's federal footprint.
JCVI operates as a prime on 77% of its awards and as a subcontractor on 23%, with named sub-award participation routed through primes such as Digital Infuzion LLC (data systems and analysis support for NIAID influenza research), La Jolla Institute for Immunology (epitope identification and validation), and Washington University (coronavirus vaccine development, synthetic biology, and biocontainment research). Grant sub-award work extends to a wide consortium including University of Pennsylvania (synthetic mammalian artificial chromosome construction), Emory University, University of Illinois, and University of California San Diego (microbial genomics, neurodevelopment, and coastal ecology). The organization maintains a named subsidiary, Biorentis Inc., a for-profit entity whose federal role in the award portfolio is not detailed in the source.
Quick answers
Is J. Craig Venter Institute, Inc. registered in SAM.gov?
Yes. J. Craig Venter Institute, Inc.'s SAM.gov registration is active through October 6, 2027.
Which contract vehicles does J. Craig Venter Institute, Inc. hold?
J. Craig Venter Institute, Inc. holds a place on 1 federal contract vehicle: CORE.
How much has J. Craig Venter Institute, Inc. received in federal contracts?
Federal contracts obligated $692,088 to J. Craig Venter Institute, Inc. in fiscal year 2025 and $2,380,701 in fiscal years 2023 through 2027.
How does J. Craig Venter Institute, Inc. rank among federal contractors?
J. Craig Venter Institute, Inc. ranked #61 in PSC Q3 and #88 in NAICS 54138 in FY2025.
What is J. Craig Venter Institute, Inc.'s most recent federal award?
J. Craig Venter Institute, Inc.'s most recent federal grant award is Collaborative research: changes in microbial composition and metabolite production associated with sinking particles in… (2547563), from Division of Ocean Sciences, on August 1, 2026.
On GovTribe
See J. Craig Venter Institute, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors